Professor Yohann Loriot

Professor Yohann Loriot is a university professor and hospital consultant, and a medical oncologist specialising in the management of bladder cancer. At Gustave Roussy, he serves as Deputy Head of the Department of Therapeutic Innovation and Early Trials (DITEP) and coordinates the UNLOCK programme, which focuses on analysing mechanisms of action and resistance to innovative therapies. He teaches medicine at the University of Paris-Saclay.

He holds a medical doctorate from Pierre and Marie Curie University and a PhD in anti-tumour pharmacology from the University of Paris-Saclay. In 2024, he was awarded his Habilitation à Diriger des Recherches (HDR), qualifying him to supervise research. He joined Gustave Roussy in 2009 and spent a year at the Vancouver Prostate Centre, a research institution affiliated with the University of British Columbia in Canada, where he studied resistance mechanisms to therapies targeting the androgen receptor. In 2013, he received the ASCO Conquer Cancer Foundation Young Investigator Award.

Alongside his clinical work, Professor Loriot devotes his research activities to analysing treatment resistance mechanisms in solid tumours (UNLOCK programme), identifying therapeutic targets, and developing new drugs—particularly for prostate and urothelial cancers—as well as creating preclinical models. His work has led to over 300 publications in scientific journals, including the New England Journal of Medicine. He is a member of several learned societies, such as ESMO, ASCO, and AACR, and is responsible for the European guidelines for the management of bladder tumours. He also leads the EORTC Urological Tumours Study Group.